216 related articles for article (PubMed ID: 10882704)
1. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi.
Molina J; Brener Z; Romanha AJ; Urbina JA
J Antimicrob Chemother; 2000 Jul; 46(1):137-40. PubMed ID: 10882704
[TBL] [Abstract][Full Text] [Related]
2. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts.
Molina J; Martins-Filho O; Brener Z; Romanha AJ; Loebenberg D; Urbina JA
Antimicrob Agents Chemother; 2000 Jan; 44(1):150-5. PubMed ID: 10602737
[TBL] [Abstract][Full Text] [Related]
3. Cure of short- and long-term experimental Chagas' disease using D0870.
Urbina JA; Payares G; Molina J; Sanoja C; Liendo A; Lazardi K; Piras MM; Piras R; Perez N; Wincker P; Ryley JF
Science; 1996 Aug; 273(5277):969-71. PubMed ID: 8688084
[TBL] [Abstract][Full Text] [Related]
4. In-vitro antiproliferative effects and mechanism of action of the bis-triazole D0870 and its S(-) enantiomer against Trypanosoma cruzi.
Liendo A; Lazardi K; Urbina JA
J Antimicrob Chemother; 1998 Feb; 41(2):197-205. PubMed ID: 9533461
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease.
Urbina JA; Payares G; Sanoja C; Lira R; Romanha AJ
Int J Antimicrob Agents; 2003 Jan; 21(1):27-38. PubMed ID: 12507835
[TBL] [Abstract][Full Text] [Related]
6. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts.
Guedes PM; Urbina JA; de Lana M; Afonso LC; Veloso VM; Tafuri WL; Machado-Coelho GL; Chiari E; Bahia MT
Antimicrob Agents Chemother; 2004 Nov; 48(11):4286-92. PubMed ID: 15504854
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
[TBL] [Abstract][Full Text] [Related]
8. Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
Francisco AF; Lewis MD; Jayawardhana S; Taylor MC; Chatelain E; Kelly JM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4653-61. PubMed ID: 26014936
[TBL] [Abstract][Full Text] [Related]
9. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains.
Urbina JA; Payares G; Sanoja C; Molina J; Lira R; Brener Z; Romanha AJ
Int J Antimicrob Agents; 2003 Jan; 21(1):39-48. PubMed ID: 12507836
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
Urbina JA; Payares G; Contreras LM; Liendo A; Sanoja C; Molina J; Piras M; Piras R; Perez N; Wincker P; Loebenberg D
Antimicrob Agents Chemother; 1998 Jul; 42(7):1771-7. PubMed ID: 9661019
[TBL] [Abstract][Full Text] [Related]
11. In vivo susceptibility to benznidazole of Trypanosoma cruzi strains from the western Brazilian Amazon.
Teston AP; Monteiro WM; Reis D; Bossolani GD; Gomes ML; de Araújo SM; Bahia MT; Barbosa MG; Toledo MJ
Trop Med Int Health; 2013 Jan; 18(1):85-95. PubMed ID: 23130989
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi.
Brand S; Ko EJ; Viayna E; Thompson S; Spinks D; Thomas M; Sandberg L; Francisco AF; Jayawardhana S; Smith VC; Jansen C; De Rycker M; Thomas J; MacLean L; Osuna-Cabello M; Riley J; Scullion P; Stojanovski L; Simeons FRC; Epemolu O; Shishikura Y; Crouch SD; Bakshi TS; Nixon CJ; Reid IH; Hill AP; Underwood TZ; Hindley SJ; Robinson SA; Kelly JM; Fiandor JM; Wyatt PG; Marco M; Miles TJ; Read KD; Gilbert IH
J Med Chem; 2017 Sep; 60(17):7284-7299. PubMed ID: 28844141
[TBL] [Abstract][Full Text] [Related]
13. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain.
Camandaroba EL; Reis EA; Gonçalves MS; Reis MG; Andrade SG
Rev Soc Bras Med Trop; 2003; 36(2):201-9. PubMed ID: 12806455
[TBL] [Abstract][Full Text] [Related]
14. Successful Aspects of the Coadministration of Sterol 14α-Demethylase Inhibitor VFV and Benznidazole in Experimental Mouse Models of Chagas Disease Caused by the Drug-Resistant Strain of Trypanosoma cruzi.
Guedes-da-Silva FH; Batista DDGJ; Da Silva CF; Pavão BP; Batista MM; Moreira OC; Souza LRQ; Britto C; Rachakonda G; Villalta F; Lepesheva GI; Soeiro MNC
ACS Infect Dis; 2019 Mar; 5(3):365-371. PubMed ID: 30625275
[TBL] [Abstract][Full Text] [Related]
15. Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease.
Guedes PM; Oliveira FS; Gutierrez FR; da Silva GK; Rodrigues GJ; Bendhack LM; Franco DW; Do Valle Matta MA; Zamboni DS; da Silva RS; Silva JS
Br J Pharmacol; 2010 May; 160(2):270-82. PubMed ID: 20128813
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of Chagas disease.
Urbina JA
Curr Pharm Des; 2002; 8(4):287-95. PubMed ID: 11860367
[TBL] [Abstract][Full Text] [Related]
17. Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs.
Urbina JA; McKerrow JH
Antimicrob Agents Chemother; 2015 Dec; 59(12):7923-4. PubMed ID: 26578701
[No Abstract] [Full Text] [Related]
18. Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres.
Molina J; Urbina J; Gref R; Brener Z; Rodrigues Júnior JM
J Antimicrob Chemother; 2001 Jan; 47(1):101-4. PubMed ID: 11152439
[TBL] [Abstract][Full Text] [Related]
19. Reply to "Drug Susceptibility of Genetically Engineered Trypanosoma cruzi Strains and Sterile Cure in Animal Models as a Criterion for Potential Clinical Efficacy of Anti-T. cruzi Drugs".
Francisco AF; Lewis MD; Jayawardhana S; Taylor MC; Chatelain E; Kelly JM
Antimicrob Agents Chemother; 2015 Dec; 59(12):7925. PubMed ID: 26578702
[No Abstract] [Full Text] [Related]
20. Outcome of E1224-Benznidazole Combination Treatment for Infection with a Multidrug-Resistant Trypanosoma cruzi Strain in Mice.
Diniz LF; Mazzeti AL; Caldas IS; Ribeiro I; Bahia MT
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
